5. Provision of tissue from two archival tumour tissue samples (either from diagnostic biopsy, and/or primary surgery, or where available residual disease post-neoadjuvant chemotherapy). If only one tumour sample is available, the site should inform the ICR-CTSU who will discuss eligibility with the Chief Investigator or if unavailable the designated Trial Management Group (TMG) member. Patients who have tumours previously sequenced outside the c-TRAK TN trial must provide one archival tumour tissue sample and the report that confirms the mutations detected.